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P ulmonary enteric adenocarcinoma (PEAC) is classified as a subtype of pulmonary adenocarci-
noma in the World Health Organization (WHO) 
Classification of Lung Tumors [1].  This rare non-small 
cell lung cancer (NSCLC) is characterized by a > 50% 
enteric component,  histological heterogeneity with 
some components resembling lung adenocarcinoma 
such as lepidic growth,  and the expression of at least 
one immunohistochemical marker of enteric differenti-
ation,  e.g., caudal type homeobox 2 (CDX2),  cytokera-
tin (CK) 20,  and/or mucin 2 (MUC2) [2].  Differential 
diagnosis between PEAC and metastatic colorectal 
cancer is critical because of significant differences in 
prognosis and therapeutic strategies [3 , 4].  To accom-
plish this,  most reports have focused on the morpho-
logical and immunohistochemical features of PEAC 
[4 , 5].  However,  due to the rarity of this tumor type,  its 
molecular features remain relatively unexplored.
The identification of several driver mutations in 
NSCLCs has led to the development of various molecu-
lar targeting therapies,  including epidermal growth 
factor receptor (EGFR)-tyrosine kinase inhibitors 
(TKIs) and anaplastic lymphoma kinase (ALK) inhibi-
tors.  These advances have improved the prognosis of 
patients with NSCLC.  Mutations in BRAF are known 
driver mutations,  with a frequency of 1.4% in NSCLC 
(COSMIC: Catalogue of Somatic Mutations in Cancer,  
available from: https://cancer. sanger. ac. uk/cosmic,  
accessed on February 1,  2021).  The most frequent 
BRAF mutation is V600E,  followed by G469A [6 , 7].
Here,  we report a case of PEAC harboring a gly-
cine-to-valine substitution at amino acid position 469 
(G469V) of BRAF,  a minor mutation in lung adenocar-
cinomas,  much rarer in colorectal cancer.
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Pulmonary enteric adenocarcinoma (PEAC) is a rare subtype of lung cancer that should be differentiated from 
colorectal cancer metastasis.  Little is known about its genetic background.  An 84-year-old male with adeno-
carcinoma of the lung underwent left upper lobectomy.  The histology of the surgical specimen was suggestive of 
PEAC.  Gastrointestinal and colorectal fiberscopy revealed no evidence of colorectal cancer.  Next-generation 
sequencing of the tumor identified a G469V substitution in serine/threonine-protein kinase B-raf (BRAF).  
Based on the higher prevalence of the G469 substitution in BRAF-mutant lung adenocarcinoma than in BRAF-
mutant colorectal cancer,  the tumor likely originated from the lung.  Identification of mutational genotype may 
be of some help in distinguishing PEAC from the lung metastasis of colorectal cancer.
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Case Presentation
A computed tomography (CT) chest scan was per-
formed as part of a routine follow-up for rheumatic 
arthritis in an 84-year-old Japanese male with a history 
of smoking (16 pack-years),  and an abnormal shadow 
was observed (Fig. 1A).  The lesion appeared as a 4-cm 
tumor in the upper lobe of the left lung; a biopsy spec-
imen obtained by transbronchial biopsy was assessed 
histologically as adenocarcinoma.  A fluorine 
18-labeled fluorodeoxyglucose (FDG)-positron emis-
sion tomography (PET) scan revealed high FDG avidity 
in the left upper lobe lesion without abnormal uptake 
elsewhere,  including the hilar and mediastinal lymph 
nodes (Fig. 1B).  The patient underwent a left upper 
lobectomy with systematic lymph node dissection.  The 
resected specimen showed tubular or papillary forma-
tion of tall-columnar tumor cells with eosinophilic 
cytoplasm and tall or ovoid nuclei (Fig. 2A and 2B).  
Nuclei were arranged in a palisading or pseudostratified 
pattern (Fig. 2B).  The sample also displayed heteroge-
neous features,  such as alveolar replacement 
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Fig.  1　 A,  Computed tomography (CT) scan indicating a consolidated mass in the upper lobe of the left lung (black arrow);  
B,  Fluorine 18-labeled fluorodeoxyglucose (FDG)- positron emission tomography (PET) showing high FDG accumulation in the lesion in the 
upper lobe of the left lung (white arrow),  but no abnormal uptake in the abdominal region.
Fig.  2　 A,  Hematoxylin-eosin staining of a surgically resected specimen showing a tubular or papillary pattern of tumor growth;  
B,  Tumor cells were columnar,  with pseudostratified nuclei and apically oriented eosinophilic cytoplasm; C,  Immunohistochemistry of 
cytokeratin (CK) 7; (D) CK20 and (E) CDX2 were positive,  negative and partially positive,  respectively.
patterns  and micropapi l lar y  prol i ferat ion.  
Immunohistochemical staining was CK7-positive and 
CK20-negative (Fig. 2C and 2D).  CDX2,  which is a 
sensitive and specific marker for primary and metastatic 
colorectal adenocarcinomas,  was partially positive 
(Fig. 2E).  According to the WHO Classification of Lung 
Tumors [1],  PEAC was strongly suspected.  
Gastrointestinal and colorectal fiberscopy revealed no 
malignant lesions in the gastrointestinal tract.
To investigate the mutational profile of the resected 
tumor,  we obtained the patient’s permission to perform 
next-generation DNA sequencing (NGS) using the 
ClearSeq CancerHS Panel (Agilent Technologies),  which 
is designed to identify somatic variants in 47 cancer-re-
lated genes including EGFR, KRAS, NRAS, BRAF, RET, 
PIK3CA and TP53.  This NGS analysis was approved by 
the Ethics Committee of Okayama University Graduate 
School of Medicine,  Dentistry and Pharmaceutical 
Sciences and Okayama University Hospital (approved 
number: K1609-042).  Among the 47 genes examined 
by this assay,  only the BRAF gene showed a mutation 
(G469V).  
Unfortunately,  while the patient remained free from 
cancer recurrence,  he died 3.5 years after the tumor 
resection due to acute respiratory distress syndrome 
caused by pneumonia.  Prior to his death,  he provided 
written informed consent for publication of his case 
history and NGS results.
Discussion
We report a case of PEAC harboring the BRAF 
G469V mutation,  which is rare but known to be one of 
the oncogenic driver mutations in NSCLC.
Gene mutational analyses for PEAC have been 
reported.  Among them,  Nottegar et al. reported that 
more than half of the 46 PEAC cases they examined 
harbored KRAS mutations [8].  They also reported 
EGFR mutations,  phosphatidylinositol 3-kinase cata-
lytic subunit alpha (PIK3CA) mutations and ALK rear-
rangements but no BRAF mutations [8].  A more recent 
paper reported 13 cases of PEAC,  including 2 cases of 
BRAF-mutated PEAC; however,  no mutational geno-
types of BRAF were described [9].  Regarding the onco-
genic significance of BRAF mutations in codon 469 
within exon 11 encoding a P-loop in the kinase domain,  
the G469A mutation is reported to be associated with 
increased BRAF kinase activity and downstream extra-
cellular signal-regulated kinase (ERK) 1/2 phosphory-
lation [6].  Our group demonstrated that exogenous 
overexpression of G469V-mutated BRAF,  like the 
G469A mutant,  activates the downstream BRAF signal-
ing pathway [10].  A similar effect of these two types of 
amino acid substitutions is reasonable,  as the replaced 
alanine and valine in codon 469 are both small hydro-
phobic amino acids,  whereas the original glycine in 
codon 469 is a neutral amino acid,  implying that 
G469A/V is disease-causing.  Therefore,  the G469V 
mutation detected in the present case seems to be 
responsible for the tumorigenesis of PEAC.  
The particular mutational genotype in our case,  a 
G469V substitution,  was helpful in determining the 
pathological diagnosis.  According to COSMIC v94 
(https://cancer.sanger.ac.uk/cosmic,  genome version 
GRCh38,  accessed on June 2,  2021),  11762 out of 
95203 tested samples (12.4%) of colon cancer harbored 
a BRAF mutation,  of which the vast majority 
(11207 ; 95.3%) had the V600E substitution.  The 
G469A/V mutation was detected in only 16 samples 
(0.1%).  In lung cancer,  714 out of 30,186 tested sam-
ples (2.4%) were positive for BRAF mutation.  Among 
the 714 BRAF-mutated lung cancers,  the number of 
samples with V600E and G469A/V mutations were 
317 (44.4%) and 101 (14.1%),  respectively.  In total,  
138 cases of cancer samples with the BRAF G469A 
mutation have been reported.  Among these,  72 sam-
ples (52.2%) and 11 samples (8.0%) originated from the 
lung and large intestine,  respectively.  Similarly,  among 
54 samples of cancers harboring the G469V mutation,  
29 (53.7%) and 5 (9.3%) originated from the lung and 
large intestine,  respectively.  These data suggest that 
from a statistical point of view,  lung tumors with the 
BRAF G469A/V mutation are more likely to originate 
from the lung tissue than from the colon.  Although 
showing morphological characteristics similar to those 
of colorectal adenocarcinoma,  the present case may 
have a molecular signature of lung adenocarcinoma 
rather than colorectal adenocarcinoma.  Zhang et al. 
reported that 75% of PEAC patients harbored an 
NSCLC-specific driver mutation such as EGFR or ALK 
fusion gene and that those mutations can distinguish 
PEAC from pulmonary metastasis of colon cancer [9].  
Their analysis shows that mutational profile plays a crit-
ical role in the diagnosis of PEAC,  just as our case 
seems to suggest.  It is possible that mutational analysis 
can be helpful to distinguish PEAC from metastasis of 
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colorectal cancer.  Further accumulation of genetic 
information about PEAC is useful for differential diag-
nosis of PEAC by genetic analysis.
Detection of a non-V600E BRAF mutation in PEAC 
is also significant with regards to therapeutic approach.  
Second-generation RAF inhibitors,  such as vemu-
rafenib and dabrafenib,  have selective activity against 
V600E-mutated BRAF [11 , 12],  but have limited effi-
cacy in BRAF non-V600E mutant cell lines [13].  Thus,  
in the upcoming era of precision medicine,  targeted 
molecular therapies for non-V600E BRAF mutations 
such as LY3009120,  a novel pan-RAF inhibitor,  will 
play important roles in the treatment of NSCLC [10].  
Defining the specific BRAF mutational genotype of each 
patient with comprehensive NGS gene analysis will be 
clinically important in personalized gene-targeting 
medicine.
Conclusion
We report a case of PEAC harboring a rare BRAF 
G469V mutation.  Although further investigation is 
needed,  distinguishing the exact mutational genotype 
may be beneficial in both diagnosing PEAC and select-
ing the appropriate molecular-targeting therapy.
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